The interplay between diet, the microbiota and immunity
Research in mice shows how diet alters immune system function through a gut microbe
At a glance:
- Research in mice demonstrates how diet alters a gut microbe molecule that in turn prompts immune cells to downregulate inflammation
- Study illustrates the molecular mechanism behind the longstanding view that diet, microbiota and immunity influence each other in myriad ways
- Following more testing, findings could inform the design of small-molecule drugs that regulate immune response to treat inflammatory conditions
An international team of researchers including Monash University have found molecular proof of how diet ultimately affects immunity through the gut microbiome.
The team’s work, conducted in mice, have pinpointed a microbial molecule called B. fragilis that sets off an immune-signalling cascade triggered by the host’s diet of a metabolic breakdown of branch-chained amino acids in the mouse gut.
The multistep pathway begins with B. fragilis taking up the branch-chained amino acids and then converting them by a specific enzyme into sugar-lipid molecules that also have branched chains that are then spotted and picked up by a class of immune-signalling cells known as antigen-presenting cells, which in turn induce natural killer T (NKT) cells to exercise their immunoregulatory response through upregulating inflammation-controlling genes and immune-regulatory chemicals.
Furthermore, the team found that B. fragilis alters the structure of the sugar-lipid molecules that it metabolizes and renders them better capable of binding to receptors on specific immune cells and initiating a signalling cascade that culminates in downregulating inflammation.
The findings, published November 10 in Nature, offer a unifying explanation for the complex interplay between diet, gut microbiota and immune function. They are the result of collaboration among scientists at Harvard Medical School, Brigham and Women’s Hospital, Seoul National University, and Monash University in Australia.
NKT cells line the human gastrointestinal tract, the lungs and are also found in the liver and spleen and likely play a significant role in immune regulation and are implicated in a range of inflammatory conditions including ulcerative colitis, and to a possible role in airway inflammatory conditions, such as asthma.
While scientists have surmised for a long time that diet plays a role in immune health, the new study elucidates the precise molecular cascade behind diet and immune health, said study senior author Dennis Kasper, professor of immunology at Harvard Medical School.
“We have shown how diet affects the immune system through a microbe mediator in the gut, and this is a really striking example of the diet-microbiota-immunity triad at play,” Kasper said. “What this work really does is provide a step-by-step pathway from beginning to end that explains how and why this triad works and how diet ultimately affects the immune system.”
Using a structural biology approach, Professor Jamie Rossjohn, ARC Laureate Fellow at the Monash Biomedicine Discovery Institute, elucidated how the lipid structure engages with and binds to antigen-presenting cells—the immune cells that give NKT cells the go-ahead to produce anti-inflammatory chemicals.
“This work offers a great example of trans-disciplinary discovery-based research aimed at answering a major question in biomedical sciences, namely how the immune system can be modulated by the interplay between diet and the microbiota,” Professor Rossjohn said.
Study coinvestigator Seung Bum Park, professor of chemistry at Seoul National University, synthesized and the Harvard team tested 23 different configurations of the microbe-made immunomodulatory molecule to determine how each one interacts with the immune cells that regulate inflammation.
“Our new work demonstrates that the branching of the lipid structure induces a very different response—the branching in the structure induces an anti-inflammatory rather than a proinflammatory response,” Professor Kasper said.
Co-authors included Sungwhan F. Oh, T. Praveena, Heebum Song, Ji-Sun Yoo, Da-Jung Jung, Deniz Erturk-Hasdemir1, Yoon Soo Hwang, ChangWon Lee, Jérôme Le Nours, Hyunsoo Kim, Jesang Lee, and Richard Blumberg.
Read the full paper in Nature titled: Host immunomodulatory lipids created by symbionts from dietary amino acids.DOI: 10.1038/s41586-021-04083-0
For media enquiries please contact:
T: +61 (0) 425 725 836
For more Monash media stories, visit our news and events site
About the Monash Biomedicine Discovery Institute at Monash University
Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Spanning six discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection and Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.
Oh, Blumberg, and Kasper have filed a patent for Bacteroides fragilis α-galactosylceramides(BfaGCs) and related structures. Oh, Park, and Kasper have filed a patent on the functions of BfaGCs and related structures.